Síguenos en Twitter     Síguenos en Facebook     Síguenos en YouTube     Siguenos en Linkedin     Correo Grupsagessa     Gmail     Dropbox     Instagram     Google Drive     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon

SOBRE EL AUTOR **

Mi foto
FACP. Colegio de médicos de Tarragona Nº 4305520 / fgcapriles@gmail.com

WORLD EMERGENCY MEDICINE SOCIETIES & RELATED

Search

Content:

miércoles, 19 de agosto de 2020

Covid-19 and Colchicine

R.E.B.E.L. Covid-19 - August 17, 2020 - By Salim Rezaie
Paper: Deftereos SG et al. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized with Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial. JAMA Net Open 2020. PMID: 32579195
“Clinical Question: Is the use of colchicine among patients hospitalized with symptomatic COVID-19 associated with clinical benefit?
Author Conclusion: “In this randomized clinical trial, participants who received colchicine had statistically significantly improved time to clinical deterioration. There were no significant differences in high-sensitivity cardiac troponin or C-reactive protein levels. These findings should be interpreted with caution.”
Clinical Take Home Point: Although the observed clinical difference in decrease in clinical deterioration with the addition of colchicine to standard medical therapy is impressive, these results should be considered hypothesis generating due to the size of the trial and the issues in the methodology These results would need to be replicated in a larger trial, with more clinical events before implementing the use of colchicine into clinical treatment of COVID-19”